Keiretsu Capital
Keiretsu Capital invests in emerging companies alongside angel investors, providing additional round and follow-on capital. It supports portfolio companies by helping them connect with syndicate partners, venture capitalists, corporate investors and public markets.
Facts
- HQ
- Seattle, WA, US
- Founded
- 2013
- Employees
- 2–10
Is this your organization? Claim it
Healionics Raises $5.5M to Complete Human Trial of STARgraft Artificial Blood Vessel for Dialysis Patients
Healionics, a Seattle-based medical tech company, raised $5.5 million to complete human trials and pursue regulatory approval for its STARgraft artificial blood vessel designed for dialysis patients. The STARgraft aims to provide a durable vascular access solution resistant to blockages and infections that commonly affect dialysis patients.
Healionics raises $4.7M led by Keiretsu Capital to commercialize STARgraft artificial blood vessel, aims for early‑next‑year launch
Seattle medical device company Healionics raised $4.7 million led by Keiretsu Capital to commercialize STARgraft, a synthetic vascular graft designed to resist occlusion for dialysis patients, and plans a commercial launch early next year. The funding will finance a second human study and FDA clearance efforts; the company also converted $5.2 million of notes and interest into equity.
LumiThera raises $14M to complete LIGHTSITE III trial and pursue U.S. clearance for Valeda
LumiThera, a Poulsbo, Wash. medical device startup, raised $14 million to finish enrollment in its LIGHTSITE III U.S. trial and seek U.S. regulatory clearance for Valeda, a photobiomodulation device for dry age-related macular degeneration already approved in the EU.
Online
Questions about Keiretsu Capital
What is Keiretsu Capital?
Seattle, WA, US
Where is Keiretsu Capital based?
Keiretsu Capital is headquartered in Seattle, WA, US.
When was Keiretsu Capital founded?
Keiretsu Capital was founded in 2013.
How many people work at Keiretsu Capital?
Keiretsu Capital has 2–10 employees.